

Hugh S Griffith
Chief Executive Officer
T: +44 (0) 131 248 3660
E: info@nucanabiomed.com
W: www.nucanabiomed.com

Edinburgh, U.K., 10 March 2014

## NuCana to present at AACR in San Diego, April 2014

NuCana today announced that it will be presenting at the forthcoming American Association for Cancer Research (AACR) annual meeting in San Diego CA, in April 2014. NuCana will present a detailed review of the non-clinical studies with its lead anti-cancer agent, Acelarin™ (NUC-1031) on the 9th of April 2014, 8:00-12:00; Hall A-E, Poster Section 38. Additional pharmacokinetic and cellular uptake data will also be presented from the ongoing Phase I/II clinical study (ProGem 1) in patients with advanced cancer.

Acelarin is the first of NuCana's ProTide portfolio to enter clinical studies and is already achieving high disease control across a broad range of rapidly progressing cancers. Three more anti-cancer ProTides are in the IND enabling stage and are expected to enter the clinic over the next 12 to 18 months. This collection of potent anti-cancer agents, generated through the ProTide platform, provides NuCana with a strong, diversified portfolio of products.

## About NuCana

NuCana is a clinical stage biopharmaceutical company developing and commercialising a range of exciting, new anti-cancer medicines. With its next generation of anti-cancer agents (nucleotide analogues), NuCana is setting new benchmarks for innovative therapeutic treatments. The state-of-the-art ProTide technology transforms existing therapies into better and safer medicines that overcome key cancer resistance mechanisms.

For further information, please visit www.nucana.com

## About ProTides

The distinctive feature of a ProTide is the ability to bypass the key cancer cell resistance pathways and generate high levels of the active agent inside the cancer cells. The fundamental aspect of the ProTide technology platform is the addition of a phosphoramidate moiety onto a nucleoside analogue scaffold. As such, it is applicable to all nucleoside analogues. NuCana's vision is to replace all commonly used nucleoside analogue-based treatments with more active and safer ProTides.

## About AACR

AACR is the world's first and largest professional organisation focused on advancing cancer research. AACR membership includes over 34,000 laboratory, researchers; clinicians; other health care professionals; and anti-cancer advocates from over 90 countries. AACR canvases the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis and treatment of cancer by annually convening more than 20 conferences and educational workshops, the largest of which is the AACR Annual Meeting with more than 17,000 attendees.